Hot Topics in Cardiovascular Risk Reduction: In Pursuit of Improved Cardioprotective Outcomes

1.00 CME
1.00 CME with ABIM MOC
60 MINS
$0 FEE
SAVE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Hot Topics in Cardiovascular Risk Reduction: In Pursuit of Improved Cardioprotective Outcomes

Overview

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education


Support Statement

This activity is supported by an educational grant from Amarin Pharma Inc.


Activity Description

Cardiovascular disease (CVD) continues to be the leading cause of preventable death in the United States, despite therapeutic advances. Because hyperlipidemia is a major risk factor for CVD, the treatment of elevated cholesterol, particularly low-density lipoprotein cholesterol (LDL-C), has been a major focus of preventive therapy. Notably, high triglyceride levels are independently associated with an increased risk of CVD after adjustment for LDL-C levels. Patients presenting with hypertriglyceridemia may also have multiple CVD risk factors. In this CME activity, experts summarize new evidence regarding reduction of cardiovascular (CV) risk including subset analyses from CV outcomes trials and the potential impact of this on patient management. This “In Case You Missed…” web activity features clinical experts covering key abstracts and publications from recent cardiology meetings.


Target Audience

The intended audience for this activity is cardiologists, interventional cardiologists, internists, endocrinologists, and other health care professionals involved in the management of patients with cardiovascular risk.


Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Apply the evidence regarding reduction of cardiovascular (CV) risk by decreasing low-density lipoprotein cholesterol (LDL-C).
  • Select patients that may benefit from further treatment to reduce risk of CV events despite having other risk factors under control.
  • Implement the most recent clinical evidence including subset analyses from CV outcomes trials regarding reduction of CV risk and potential impact on patient management.

Activity Chair

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
Executive Director of Interventional Cardiovascular Programs
Brigham and Women’s Hospital Heart and Vascular Center
Professor of Medicine
Harvard Medical School
Boston, MA


Faculty

Martha Gulati, MD, MS, FACC, FAHA, FASPC
Division Chief of Cardiology, University of Arizona-Phoenix—Professor of Medicine
Editor-in Chief of CardioSmart for the American College of Cardiology
Phoenix, AZ

Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC
Associate Professor of Medicine & Epidemiology
Director of Women’s Cardiovascular Health
Associate Director of Preventive Cardiology
Ciccarone Center for the Prevention of Cardiovascular Disease
Johns Hopkins University School of Medicine
Baltimore, MD


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

abimSuccessful completion of this CME activity enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, March 31, 2021, to March 30, 2022.


How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 of the 4 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.


Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.  

Activity Chair and Faculty report the following relationship(s)

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
Contracted Research: Abbott Medical Optics, Aimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, MyoKardia, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi-Aventis, Synaptic, The Medicines Company

Martha Gulati, MD, MS, FACC, FAHA, FASPC
No relevant financial relationships to disclose.

Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC
No relevant financial relationships to disclose.

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose. 

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CME Questions?

Contact us at cme@vindicoCME.com